MA40968A - Polythérapie à base d'anticorps anti-egfr - Google Patents

Polythérapie à base d'anticorps anti-egfr

Info

Publication number
MA40968A
MA40968A MA040968A MA40968A MA40968A MA 40968 A MA40968 A MA 40968A MA 040968 A MA040968 A MA 040968A MA 40968 A MA40968 A MA 40968A MA 40968 A MA40968 A MA 40968A
Authority
MA
Morocco
Prior art keywords
antibodies
polytherapy
egfr antibody
adc
antibody
Prior art date
Application number
MA040968A
Other languages
English (en)
Inventor
Ilia Alexandre Tikhomirov
Original Assignee
Formation Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Formation Biologics Inc filed Critical Formation Biologics Inc
Publication of MA40968A publication Critical patent/MA40968A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Les anticorps anti-egfr peuvent être combinés pour améliorer leur effet anticancéreux. Dans la présente invention, au moins l'un de deux anticorps nus dans une combinaison est fourni en tant que conjugué de médicament d'anticorps (adc) dans lequel l'anticorps est couplé à une cytotoxine. Les deux anticorps peuvent également être fournis sous forme d'adc. Le résultat est une activité améliorée, l'amélioration étant synergique dans de nombreuses paires d'anticorps de ce type.
MA040968A 2014-10-31 2015-10-30 Polythérapie à base d'anticorps anti-egfr MA40968A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462073380P 2014-10-31 2014-10-31

Publications (1)

Publication Number Publication Date
MA40968A true MA40968A (fr) 2017-10-04

Family

ID=55856303

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040968A MA40968A (fr) 2014-10-31 2015-10-30 Polythérapie à base d'anticorps anti-egfr

Country Status (5)

Country Link
US (1) US20170333570A1 (fr)
EP (1) EP3223857A4 (fr)
CA (1) CA2965362A1 (fr)
MA (1) MA40968A (fr)
WO (1) WO2016065456A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472371B (zh) * 2016-07-05 2022-05-24 江苏恒瑞医药股份有限公司 Egfr抗体-药物偶联物及其在医药上的应用
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703243B (zh) * 2002-10-10 2011-05-04 默克专利有限公司 针对erb-b1受体的药物组合物
MX338151B (es) * 2007-03-01 2016-04-05 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
EP2566512A1 (fr) * 2010-05-04 2013-03-13 Merrimack Pharmaceuticals, Inc. Anticorps contre le récepteur du facteur de croissance épidermique (egfr) et leurs utilisations
US8790649B2 (en) * 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
US10570211B2 (en) * 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
ME03353B (fr) * 2011-03-29 2019-10-20 Immunogen Inc Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
KR20140105765A (ko) * 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
KR102305226B1 (ko) * 2013-03-15 2021-09-29 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형

Also Published As

Publication number Publication date
EP3223857A1 (fr) 2017-10-04
CA2965362A1 (fr) 2016-05-06
WO2016065456A1 (fr) 2016-05-06
US20170333570A1 (en) 2017-11-23
EP3223857A4 (fr) 2018-06-27

Similar Documents

Publication Publication Date Title
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
MA35035B1 (fr) Anticorps polypeptidiques qui antagonisent les cd40
EP3470424A4 (fr) Séquence de région constante à chaîne lourde d'anticorps pour améliorer l'activité d'anticorps agonistes
EP3442973A4 (fr) Nouveaux composés utilisés en tant qu'inhibiteurs de l'autotaxine et compositions pharmaceutiques les comprenant
EP3665195A4 (fr) Variants d'anticorps fc modifiés pour demi-vie sérique améliorée
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
MA39254A1 (fr) Anticorps stables à affinité élevée et agrégatifs à base de domaines viraux vl et de dérivé de vhh
MX2015011778A (es) Combinacion de farmaco.
ECSP16068524A (es) Insulina de acción prolongada y uso de la misma
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
EP3437646A4 (fr) Préparation orale présentant une exceptionnelle aptitude à l'élution
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
ZA202107826B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EP3313380A4 (fr) Composition pour l'administration d'agents actifs à un animal
EP3885362A4 (fr) Conjugué d'anticorps
EP3498272A4 (fr) Préparation pour absorption transdermique comprenant de l'oxybutynine
MA50862A (fr) Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30
MA40968A (fr) Polythérapie à base d'anticorps anti-egfr
EP3668991A4 (fr) Nanosupports pour l'administration de principes actifs